Search


Important Information for the Hemophilia Community Regarding Triad Group’s Alcohol Prep Products and Bayer’s BayCuff™ and First Aid Kit… learn more »

Kogenate FS Logo - antihemophilic factor (recombinant) for the treatment of Hemophilia A

The most serious adverse reactions are systemic hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to AHF. Continue Reading Below »

What’s New For People with Hemophilia A?

At Bayer HealthCare Pharmaceuticals Inc., we are constantly innovating to provide you with treatment options. Stay Informed on the latest treatment news by email, or read the most recent news releases from Bayer HealthCare Pharmaceuticals.

FDA Approves 3000 IU Vial Size for Kogenate® FS, antihemophilic factor (recombinant) August 7, 2009

Larger Vial Provides Greater Convenience for Patients Requiring Higher Dose

See the full news release here.

Bayer HealthCare Launches Hemophilia Self-Infusion Training Program July 9, 2009

Innovative BayCuff™ Program Empowers Young Members of Hemophilia A Community to Take Control of Their Treatment

See the full news release here.

INDICATIONS & USAGE

Kogenate® FS, antihemophilic factor (recombinant), is a recombinant factor VIII treatment indicated for the control and prevention of bleeding episodes and peri-operative management in adults and children (0-16 years) with hemophilia A. Kogenate® FS is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no preexisting joint damage.

IMPORTANT SAFETY INFORMATION

The most serious adverse reactions are systemic hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to AHF. The most common adverse reactions observed in clinical trials were inhibitor formation in previously untreated or minimally treated patients, skin-associated hypersensitivity reactions, infusion site reactions, and central venous access device (CVAD) line-associated infections.

Kogenate® FS is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including mouse or hamster proteins.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

For important risk and use information, please see the full prescribing information.

Prescribing Information | Privacy Policy | Terms of Use | Sitemap

© 2010 Bayer HealthCare Pharmaceuticals Inc. All rights reserved.
BAYER, the Bayer Cross, and KOGENATE are registered trademarks of Bayer.
BIO-SET is a trademark of Biodome SAS.

Bayer HealthCare Pharmaceuticals

Kogenate FS Antihemophilic Factor (Recombinant) with BIO-SET Needleless Reconstitution System